A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatment.

Autor: Deodhar A; Oregon Health & Science University, Portland, OR, USA., Kivitz AJ; Altoona Center for Clinical Research, Duncansville, PA, USA., Magrey M; University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA., Walsh JA; Salt Lake City Veterans Affairs Medical Center and University of Utah School of Medicine, Salt Lake City, UT, USA., Mease PJ; Swedish Medical Center/Providence St Joseph Health and University of Washington, Seattle, WA, USA., Greenwald M; Desert Medical Advances, Palm Desert, CA, USA., Kianifard F; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Elam C; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Bommidi GM; Novartis Healthcare Pvt Ltd, Hyderabad, India., Winseck A; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Gensler LS; University of California, San Francisco, San Francisco, CA, USA.

Publikováno v: Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2024 Aug 12. Date of Electronic Publication: 2024 Aug 12.